E\u00dc Fen Fak\u00fcltesi bilim ekibinden \u00e7a\u011f\u0131n hastal\u0131\u011f\u0131n\u0131n tedavisine y\u00f6nelik proje<\/p>\n
\u00a0Kanserin tedavisinde kullan\u0131lacak yeni nesil molek\u00fcller geli\u015ftiriliyor<\/b><\/p>\n
Ege \u00dcniversitesi (E\u00dc) Fen Fak\u00fcltesi\u00a0Biyokimya B\u00f6l\u00fcm\u00fc Biyokimya Anabilim Dal\u0131 \u00f6\u011fretim \u00fcyesi Do\u00e7. Dr. Alper Akkaya sorumlulu\u011funda, Biyoloji B\u00f6l\u00fcm\u00fc Molek\u00fcler Biyoloji Anabilim Dal\u0131 \u00f6\u011fretim \u00fcyesi Do\u00e7. Dr. Sava\u015f \u0130zzeto\u011flu ve Fen Bilimler Enstit\u00fcs\u00fc Biyokimya Anabilim Dal\u0131 y\u00fcksek lisans \u00f6\u011frencisi bursiyer Ceyda \u00d6zen taraf\u0131ndan y\u00fcr\u00fct\u00fclen \u201cLaktik Asit Bakterilerinden Antimikrobiyal Peptid \u00dcretimi ve Prostat Kanserine Kar\u015f\u0131 Antikanserojenik Etkilerinin Belirlenmesi\u201d konulu proje, T\u00fcrkiye Sa\u011fl\u0131k Enstit\u00fcleri Ba\u015fkanl\u0131\u011f\u0131 (T\u00dcSEB) taraf\u0131ndan desteklemeye hak kazand\u0131. Bilimsel \u00e7al\u0131\u015fmalar\u0131 Fen Fak\u00fcltesi\u00a0Biyoteknoloji Ara\u015ft\u0131rma Laboratuvar\u0131nda s\u00fcrd\u00fcr\u00fclen proje ile kanser tedavisi i\u00e7in alternatif bir yakla\u015f\u0131m bulma ihtiyac\u0131ndan hareketle, tedavi g\u00f6ren hastalar\u0131n ya\u015fad\u0131klar\u0131 olumsuzlar\u0131 azaltmak ve n\u00fckseden kanser vakalar\u0131n\u0131n \u00f6n\u00fcne ge\u00e7mek hedefleniyor.<\/p>\n
Kanser hastal\u0131\u011f\u0131na kar\u015f\u0131 yeni tedavi molek\u00fclleri geli\u015ftirmeye \u00e7al\u0131\u015ft\u0131klar\u0131n\u0131 ifade eden Do\u00e7. Dr. Alper Akkaya, \u201cT\u00fcrkiye \u0130statistik Kurumu \u00a0verilerine g\u00f6re en y\u00fcksek \u00f6l\u00fcm oran\u0131na sahip olan hastal\u0131klar\u0131n ikincisi kanserdir. Kanserin sebep oldu\u011fu \u00f6l\u00fcmler yaln\u0131zca kanser sebebiyle de\u011fil, organlardaki yetmezlik ya da imm\u00fcn sistemin, yani ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin \u00e7\u00f6kmesi sonucuyla ortaya \u00e7\u0131kan enfeksiyon nedeniyle de ger\u00e7ekle\u015fir.\u00a0Kanser konusunda bir\u00e7ok tedavi y\u00f6ntemi mevcut. Ancak bu tedavi y\u00f6ntemlerinden \u00f6zellikle kemoterapide hastalar yan etkiler nedeniyle \u00e7ok y\u0131pran\u0131yorlar. V\u00fccut, sa\u011fl\u0131kl\u0131 h\u00fccrelerin de etkilenmesi sebebiyle kanserle sava\u015facak g\u00fcc\u00fcn\u00fc yitirmeye ba\u015fl\u0131yor. Bu noktadan sonra iyile\u015fme grafi\u011fi d\u00fc\u015f\u00fcyor. Dolay\u0131s\u0131yla kanser tedavisinde yeni molek\u00fcllere ihtiya\u00e7 oldu\u011fu ortaya \u00e7\u0131k\u0131yor.\u00a0Biz, biyoteknoloji \u00e7er\u00e7evesinde yeni tedavi molek\u00fclleri geli\u015ftirmeye \u00e7al\u0131\u015f\u0131yoruz. \u00dczerinde \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z molek\u00fcllere de ‘Antimikrobiyal Peptid (AMP)’ ad\u0131 veriliyor\u201d diye konu\u015ftu.<\/p>\n
\u201cPeptidler, h\u00fccrenin i\u00e7inden d\u0131\u015f\u0131na do\u011fru bir t\u00fcnel olu\u015fturuyorlar\u201d<\/b><\/p>\n
Proje ile antimikrobiyal ya da antikanser \u00f6zellikli yeni peptidler ortaya \u00e7\u0131karmak istediklerini dile getiren\u00a0Do\u00e7. Dr. Alper Akkaya, \u201cHer canl\u0131da bulunan peptidler, proteinlerin biraz daha k\u00fc\u00e7\u00fck yap\u0131l\u0131 halleridir ve k\u0131sa zincirli olmalar\u0131na kar\u015f\u0131n v\u00fccutta pek \u00e7ok g\u00f6revleri bulunur. Hasta oldu\u011fumuzda ba\u011f\u0131\u015f\u0131kl\u0131k sistemimiz, sistemin proteinleri olan ‘\u0130mm\u00fcnoglobulin E’ sentezleyerek v\u00fccudu korumaya \u00e7al\u0131\u015f\u0131r. Bununla birlikte b\u00fcy\u00fck oranda AMP de sentezler. \u00c7al\u0131\u015fmalar\u0131m\u0131zda mikroorganizmayla, \u00f6zellikle bakterilerle kanser h\u00fccrelerinin baz\u0131 benzerlikleri oldu\u011funu g\u00f6rd\u00fck. Bu benzerlik yo\u011fun olarak h\u00fccre zar\u0131 \u00fczerinde birbirleriyle e\u015fle\u015fiyor. Hem bakterilerin hem de kanser h\u00fccrelerinde zar\u0131n d\u0131\u015far\u0131ya bakan \u00fcst k\u0131sm\u0131 y\u00fcksek oranda eksi y\u00fck i\u00e7eriyor.\u00a0Bizim \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z AMP\u2019lerin iki etki mekanizmas\u0131 var. Birincisi; AMP h\u00fccre i\u00e7erisine giriyor ve h\u00fccre i\u00e7erisindeki ya\u015famsal faaliyeti durduracak bir etkide bulunuyor. \u0130kincisi ise; AMP, h\u00fccre zar\u0131na geliyor ve zar\u0131n kararl\u0131l\u0131\u011f\u0131n\u0131 bozuyor. Peptidler, h\u00fccrenin \u00fczerinde dizilerek h\u00fccre zar\u0131nda t\u00fcneller olu\u015fturuyorlar. B\u00f6ylece i\u00e7eride h\u00fccrelerin i\u00e7 dengesi bozuluyor. \u00c7\u00fcnk\u00fc hem d\u0131\u015fardan i\u00e7eriye hem de i\u00e7eriden d\u0131\u015far\u0131ya kontrols\u00fcz su, iyon ve k\u00fc\u00e7\u00fck molek\u00fcllerin giri\u015f-\u00e7\u0131k\u0131\u015f\u0131 ger\u00e7ekle\u015fiyor. Bu durumda h\u00fccre, ya\u015fam\u0131na devam edemiyor. Biz, aradaki benzerli\u011fi fark etti\u011fimiz i\u00e7in antimikrobiyal \u00f6zellik g\u00f6steren bir peptidin, antikanser \u00f6zellik de g\u00f6sterebilece\u011fini d\u00fc\u015f\u00fcnd\u00fck. Antikanser peptidler, \u00e7ok d\u00fc\u015f\u00fck konsantrasyonlarda olduk\u00e7a etkili olabiliyorlar. \u00c7al\u0131\u015fmalar\u0131m\u0131z neticesinde yeni bir peptid ortaya \u00e7\u0131karmaya \u00e7al\u0131\u015f\u0131yoruz. Bunu yaparken mikroorganizmalar\u0131 belirli \u015fartlarda b\u00fcy\u00fcterek bu antimikrobiyal ya da antikanser \u00f6zellikli peptidleri \u00fcretmeye \u00e7al\u0131\u015faca\u011f\u0131z.\u00a0Elde etti\u011fimiz sonu\u00e7lar\u0131n ka\u00e7 tanesinin bilinip bilinmedi\u011fini inceleyece\u011fiz. Ard\u0131ndan peptidlerden hangilerinin antikanser \u00f6zelli\u011fi g\u00f6sterdi\u011fi Biyoloji B\u00f6l\u00fcm\u00fc H\u00fccre K\u00fclt\u00fcr\u00fc Laboratuvar\u0131nda ara\u015ft\u0131r\u0131lacak\u201d dedi.<\/p>\n
Do\u00e7. Dr. Akkaya, \u201cT\u00dcSEB’den destek alan bu projemiz, asl\u0131nda ana projemizin bir dal\u0131d\u0131r. Olduk\u00e7a geni\u015f bir proje olmas\u0131n\u0131 sa\u011flayan unsur, AMP\u2019leri \u00e7e\u015fitli ko\u015fullara g\u00f6re s\u0131n\u0131fland\u0131rabilmemizdir. Her \u00f6zelli\u011fini g\u00f6z \u00f6n\u00fcnde bulundurarak belirledi\u011fimiz AMP\u2019leri \u00e7al\u0131\u015fmam\u0131z\u0131n i\u00e7ine yayd\u0131k. \u00c7al\u0131\u015faca\u011f\u0131m\u0131z bu grup sadece bir taneyken; b\u00fcy\u00fck projede 20 tane ve \u00fc\u00e7er adet alternatifleri bulunan AMP\u2019ler var.\u00a0Elimizde 120’ye yak\u0131n AMP potansiyeli var. Bunlar\u0131 sadece bir kanser t\u00fcr\u00fcne etkisi \u00fczerinde kullan\u0131p b\u0131rakamay\u0131z. \u00dcr\u00fcnlerimizin hi\u00e7birini heba etmeden, b\u00fcy\u00fck projemizde T\u00dcB\u0130TAK ve E\u00dc Bilimsel Ara\u015ft\u0131rma Projeleri Koordinat\u00f6rl\u00fc\u011f\u00fc \u00a0taraf\u0131ndan desteklenebilecek farkl\u0131 kanser t\u00fcrlerine etkileri \u00fczerine de \u00e7al\u0131\u015faca\u011f\u0131z. Potansiyel bir antikanser peptid grubu ortaya \u00e7\u0131karaca\u011f\u0131z. Ard\u0131ndan etki mekanizmalar\u0131 belirleyerek, karakterizasyon yapaca\u011f\u0131z. Son olarak \u00fcr\u00fcne do\u011fru ilerleyece\u011fiz\u201d diye konu\u015ftu.<\/p>\n
\u201cBilim insanlar\u0131ndan hedef molek\u00fcl bulmalar\u0131n\u0131 isteniyor\u201d<\/b><\/p>\n
Kanserin bilim d\u00fcnyas\u0131nda hen\u00fcz bilinmeyen proteinleri kulland\u0131\u011f\u0131n\u0131 vurgulayan Molek\u00fcler Biyoloji Anabilim Dal\u0131 \u00f6\u011fretim \u00fcyesi Do\u00e7. Dr. Sava\u015f \u0130zzeto\u011flu,\u00a0<\/b>\u201cKanser, tedavisi bir t\u00fcrl\u00fc ger\u00e7ekle\u015ftirilemeyen bir hastal\u0131k. \u00c7\u00fcnk\u00fc kanser h\u00fccresi, bizim kendi h\u00fccremiz. Biz, kendi h\u00fccremizin biyolojisini,\u00a0 biyokimyas\u0131n\u0131 hala bilmiyoruz. Bir h\u00fccrenin \u00e7al\u0131\u015fmas\u0131 i\u00e7in gereken protein say\u0131s\u0131 yakla\u015f\u0131k 10 milyar civar\u0131nda. Bilim d\u00fcnyas\u0131 \u015fu anda yakla\u015f\u0131k 1000-1500 proteini biliyor. Geri kalanlar ise hala bilinmiyor. Kanser de bu bilinmeyen proteinleri kulland\u0131\u011f\u0131 i\u00e7in tedavisi ger\u00e7ekle\u015ftirilemiyor. Tedavilerde istedi\u011fimiz sonu\u00e7lar\u0131 kolay elde edemiyoruz. \u00c7\u00fcnk\u00fc kanser h\u00fccreleri de bo\u015f durmuyor. S\u00fcrekli olarak tedaviye alternatif kendini kurtaracak yollara ba\u015fvuruyor. Tedavinin kendisini etkilemesini engelliyor. Kanser ara\u015ft\u0131rmalar\u0131 yapan D\u00fcnya Kanser Enstit\u00fcs\u00fc, bilim insanlar\u0131ndan hedef molek\u00fcl bulmalar\u0131n\u0131 istiyor. Bu hedef molek\u00fcllere kar\u015f\u0131 ila\u00e7 geli\u015ftirilmesi gerekti\u011fini s\u00f6yl\u00fcyor. Bir kanser h\u00fccresi \u00e7o\u011falmak i\u00e7in h\u00fccre zar\u0131ndaki molek\u00fclleri kullan\u0131yor. Bir h\u00fccre \u00e7o\u011fal\u0131rken mutlaka sinyal almas\u0131 gerekiyor. Sinyali de h\u00fccre zar\u0131 al\u0131yor. H\u00fccre zar\u0131 sinyal almadan i\u00e7eriye mitojenik etkenleri aktaramaz.\u00a0 Burada h\u00fccre zar\u0131na etki edecek molek\u00fcller, \u00e7ok etkili hedefler olurlar\u201d dedi.<\/p>\n
\u201cN\u00fckseden kanser vakalar\u0131n\u0131 \u00f6nlemeye \u00e7al\u0131\u015f\u0131yoruz\u201d<\/b><\/p>\n
Hastal\u0131\u011f\u0131n tedavi s\u00fcrecinin \u00f6nemine dikkat \u00e7eken\u00a0Do\u00e7. Dr. Sava\u015f \u0130zzeto\u011flu,\u00a0<\/b>\u201cBizim \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z AMP\u2019lerde hedefleme sistemi var. Ba\u011fland\u0131klar\u0131 kanser h\u00fccresini bir daha b\u0131rakm\u0131yorlar. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemimiz de d\u0131\u015far\u0131dan gelen her t\u00fcrl\u00fc molek\u00fcl\u00fc ortadan kald\u0131rmak i\u00e7in harekete ge\u00e7iyor. Biz, AMP\u2019leri v\u00fccuda verdi\u011fimizde, kan h\u00fccrelerinin ve di\u011fer h\u00fccrelerin tepkilerine de bakaca\u011f\u0131z. Antikanser peptidlerinin bir \u00f6zelli\u011fi var: Kanser h\u00fccresinde olu\u015fturduklar\u0131 holler, kemoterapide kullan\u0131lan molek\u00fcllerin i\u00e7eriye girmesini kolayla\u015ft\u0131r\u0131yor. Biz, buna sinerjik etki diyoruz. B\u00f6ylece direkt kanserli h\u00fccreye giden spesifik bir mekanizma a\u00e7m\u0131\u015f oluyoruz. Bu da kemoterapik ajanlar\u0131n daha d\u00fc\u015f\u00fck miktarda kullan\u0131lmas\u0131n\u0131 sa\u011fl\u0131yor. Ayr\u0131ca bu sistem, radyoterapi \u0131\u015f\u0131nlar\u0131n\u0131n da kanserli h\u00fccrelere girmelerini kolayla\u015ft\u0131r\u0131yor. B\u00f6ylece \u2018Sekonder Kanser\u2019 dedi\u011fimiz n\u00fckseden vakalar\u0131n da bir miktar \u00f6n\u00fcne ge\u00e7meyi hedefliyoruz. Kanser tedavisi, \u00e7ok zor olan bir tedavi. Kanserle\u015fmeden sonra insanlar\u0131n ald\u0131klar\u0131 tedavi olanaklar\u0131 \u00e7ok ac\u0131l\u0131 bir s\u00fcre\u00e7. Kanser h\u00fccreleri d\u0131\u015far\u0131dan verilen her tedavi y\u00f6ntemlerinden ka\u00e7ma yolunu buluyorlar. Ayr\u0131ca radyoterapi, kemoterapi gibi tedaviler, insanlar\u0131n sa\u011fl\u0131kl\u0131 h\u00fccrelerini de etkiliyor. \u015eu anda uygulanan kanser tedavilerinde en b\u00fcy\u00fck sorun bu. O y\u00fczden tedavi s\u00fcrecinde nokta at\u0131\u015f\u0131 yap\u0131lmas\u0131 gerekiyor. Kanser h\u00fccresi belli bir miktar \u00e7o\u011fald\u0131ktan sonra, sa\u011fl\u0131kl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerini de kendi taraf\u0131na \u00e7ekmeye ba\u015fl\u0131yor. Kanserli hastalar kanserden dolay\u0131 de\u011fil, sa\u011fl\u0131kl\u0131 h\u00fccrelerin yetersizli\u011finden dolay\u0131 hayatlar\u0131n\u0131 kaybediyorlar. O y\u00fczden kanseri, ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini kendi taraf\u0131nda \u00e7evirmeden evvel tespit edilebilmesi gerekiyor\u201d diye konu\u015ftu.<\/p>\n
\u201cMultidisipliner olarak \u00e7al\u0131\u015f\u0131yoruz\u201d<\/b><\/p>\n
Biyokimya Anabilim Dal\u0131 Y\u00fcksek Lisans \u00f6\u011frencisi bursiyer Ceyda \u00d6zen ise, \u201cProjemiz bir\u00e7ok bilim dal\u0131n\u0131 bar\u0131nd\u0131r\u0131yor. \u00d6rne\u011fin biyoproses \u00e7al\u0131\u015fmalar\u0131, enstr\u00fcmantal analiz \u00e7al\u0131\u015fmalar\u0131, mikrobiyolojik \u00e7al\u0131\u015fmalar, h\u00fccre k\u00fclt\u00fcr\u00fc deneyleri gibi pek \u00e7ok alanla birlikte multidisipliner olarak \u00e7al\u0131\u015f\u0131yoruz. Bu zenginlik proje ekibimize ve \u00e7al\u0131\u015fmalar\u0131m\u0131za b\u00fcy\u00fck bir heyecan kat\u0131yor. Toplumda \u00e7o\u011fu ki\u015finin kar\u015f\u0131 kar\u015f\u0131ya kalarak, ac\u0131 ya da kay\u0131p ya\u015fad\u0131\u011f\u0131 bir hastal\u0131k i\u00e7in bir \u00e7\u00f6z\u00fcm yolu aray\u0131\u015f\u0131nday\u0131z. Bu \u00e7\u00f6z\u00fcm yolunun bir par\u00e7as\u0131 olmak ve topluma hizmet etmek bizim i\u00e7in \u00e7ok de\u011ferli ve gurur verici\u201d dedi.<\/p>\n","protected":false},"excerpt":{"rendered":"
E\u00dc Fen Fak\u00fcltesi bilim ekibinden \u00e7a\u011f\u0131n hastal\u0131\u011f\u0131n\u0131n tedavisine y\u00f6nelik proje \u00a0Kanserin tedavisinde kullan\u0131lacak yeni nesil…<\/p>\n","protected":false},"author":2,"featured_media":15687,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,99,1,70,68],"tags":[],"class_list":["post-15686","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bilim","category-egitim","category-gncl","category-kampus","category-saglik"],"featured_image_urls":{"full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4.jpg",1500,1000,false],"thumbnail":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4-150x150.jpg",150,150,true],"medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4-768x512.jpg",640,427,true],"large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4-1024x683.jpg",640,427,true],"1536x1536":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4.jpg",1500,1000,false],"2048x2048":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4.jpg",1500,1000,false],"newsphere-slider-full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4-1280x720.jpg",1280,720,true],"newsphere-featured":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4-1024x683.jpg",1024,683,true],"newsphere-medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2023\/07\/CeydaOzen_-DocDrAlper-Akkaya_ProfDrNecdetBudak_DocDrSavasIzzetoglu-4-720x380.jpg",720,380,true]},"author_info":{"display_name":"Editor","author_link":"https:\/\/www.euegeajans.com\/index.php\/author\/editor\/"},"category_info":"Bilim<\/a> E\u011fitim<\/a> G\u00fcncel<\/a> Kamp\u00fcs<\/a> Sa\u011fl\u0131k<\/a>","tag_info":"Sa\u011fl\u0131k","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/15686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/comments?post=15686"}],"version-history":[{"count":1,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/15686\/revisions"}],"predecessor-version":[{"id":15688,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/15686\/revisions\/15688"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media\/15687"}],"wp:attachment":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media?parent=15686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/categories?post=15686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/tags?post=15686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}